solute carrier family 39 member 6Genealiases: LIV-1 · LIV1 · ZIP6
Q-omics provides the consensus-scored SLC39A6 profile across patient tissues and cancer cell-line models. SLC39A6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC39A6 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SLC39A6 RNA expression shows 21,018 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, HNSC, and BRCA as cancer lineages where SLC39A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC39A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC39A6 survival associations across molecular data types. SLC39A6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC39A6 RNA expression–survival associations across cancer types. High SLC39A6 expression shows unfavorable associations in MESO, SKCM, LIHC and ACC, but favorable associations in BRCA and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC39A6 RNA expression.
This table summarizes SLC39A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC39A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC39A6 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, LUAD, LIHC and LUSC. The HNSC box plot shows higher SLC39A6 RNA expression in tumor versus normal tissue (log2 FC = +1.498, t-test p < 0.001).
This table shows molecular features associated with SLC39A6 in patient tissues and cancer cell lines. In patient samples, SLC39A6 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC39A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
